Butterfly Network, Inc. reported Q2 2026 results showing continued investment in its Ultrasound-on-Chip™ platform and strategic licensing initiatives despite ongoing net losses. The company’s reliance on contract manufacturers Benchmark Electronics and TSMC underscores supply chain vulnerabilities and pricing pressures that remain key risks. Butterfly’s differentiated handheld ultrasound devices and embedded semiconductor programs position it uniquely within the competitive medical imaging market, but regulatory scrutiny and complex FDA approval processes temper near-term growth prospects. Strong liquidity with a current ratio above 4x provides runway to support R&D, though profitability remains distant.